Jonathan P. Foster - 20 Jun 2024 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan P. Foster
Issuer symbol
MBRX
Transactions as of
20 Jun 2024
Net transactions value
-$2,404
Form type
4
Filing time
21 Jun 2024, 17:01:28 UTC
Previous filing
18 Jun 2024
Next filing
25 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +2,712 +45% 8,723 20 Jun 2024 Direct F1
transaction MBRX Common Stock Tax liability $2,404 -636 -7.3% $3.78 8,087 20 Jun 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -2,712 -3.8% $0.000000 69,166 20 Jun 2024 Common Stock 2,712 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.